Graft Outcomes of Antibody Mediated Rejection without Donor Specific Anti – HLA Antibodies After Kidney Transplantation
Investigating the HLA Alloimmune Background of the Histological Changes Suggestive of Antibody-mediated Injury in the Absence of Donor-specific Anti-HLA Antibodies
Membrane versus Centrifuge‑Based Therapeutic Plasma Exchange to Treat Antibody-Mediated Rejection in Kidney Transplantation
Outcomes of Kidney Transplant Recipients with Antibody-mediated Allograft Rejection: A Retrospective Study
Plasma Donor-Derived Cell-Free DNA Levels Risk-Stratify Kidney Allograft Injury with Isolated Transplant Glomerulitis
Prospective Intensive Monitoring for Anamnestic DSA Responses Allows Near Elimination of Early Clinical AMR
The Clinical Significance of Preformed Anti-HLA-DQ Donor-specific Antibodies on Allograft Outcomes in Kidney Transplantation
The Clinical Significance of Preformed C1q-binding Donor-specific HLA Antibodies in Kidney Transplantation
The Role of Donor-derived Cell-free DNA Testing in Detecting Subclinical Kidney Allograft Rejection
The Trifecta Study: Calibrating Circulating Donor-Derived Cell-Free DNA at the Time of Indication Biopsies Against the Molecular Phenotype of the Biopsy Reveals a Prominent Association with NK Cell Genes
2021 American Transplant Congress